Evommune, Inc. (EVMN) stock forecast and price target
Price $7.63 · data as of November 13, 2026
12-month price target
Average target$21.89
Upside / downside+186.9%
Analysts9
ConsensusBuy
Low $8.00Average $21.89High $28.00
Gold marker: average target · white marker: today’s price ($7.63)
Analyst ratings
Strong buy 4Buy 5Hold 3Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-3.28 | +70.7% | $625000 |
| Next fiscal year ends December 31, 2027 | $-3.42 | −4.3% | $875000 |
| Next quarter ends December 31, 2026 | $-0.98 | +31.2% | $625000 |
| Quarter after ends March 31, 2027 | $-0.87 | — | $0 |
Consensus of the analysts covering Evommune, updated daily. In the last 30 days 1 estimates were raised and 1 lowered.
Frequently asked questions
What is the Evommune stock price target?
The average 12-month target from 9 analysts is $21.89, 186.9% above the current price of $7.63 Targets range from $8.00 to $28.00.
Is Evommune a buy according to analysts?
The consensus rating is “Buy” (4 strong buy, 5 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Evommune expected to earn?
Analysts expect EPS of $-3.28 for the fiscal year ending December 31, 2026 and $-3.42 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.